A US patent victory could give Amgen’s Enbrel another eight years’ patent exclusivity, but is the enthusiasm justified?
In blaming bempegaldesleukin’s falling efficacy on poor manufacturing Nektar has alarmed investors even more.
Blaming manufacturing delays and competitive pressure, Autolus asks investors to reset expectations.
Vascular robotics is growing fast and Corindus is the leader here, but Healthineers will need an aggressive sales plan.
Bayer has responded to its current woes by going all in on cell therapy – a move that, even if successful, will take a long time to pay off.
As Lynparza threatens Rubraca in prostate cancer, investors should now focus on whether Astra will show a benefit in the ATM-mutant patient population.
Setmelanotide looks approvable, but patients were stratified for inclusion in some measures.
The company’s Enigma study in an orphan digestive tract disease points a way to approval, notwithstanding the company’s statistical analysis method.
The failure of its lead sickle cell project forces Glycomimetics to pivot to a leukaemia asset, but the company’s approach has taken a huge blow.